Equibles does not estimate personal net worth.
Get an email with a short summary when Puma Biotechnology, Inc. publishes a filing, an earnings call transcript or a press release.
Get PBYI alertsMaximo Nougues is recorded as CFO at Puma Biotechnology, Inc. (PBYI). The newest filing on record that lists Maximo Nougues as CFO at Puma Biotechnology, Inc. (PBYI) is dated April 28, 2026. The proxy statement of Puma Biotechnology, Inc. reports total compensation of $1,241,215 for Maximo Nougues in fiscal 2025, including a base salary of $562,961. Disclosed compensation is on record for 8 fiscal years. Maximo Nougues has spoken on 25 earnings calls and 1 other investor event across 1 company, most recently for Puma Biotechnology, Inc. on September 14, 2026. Puma Biotechnology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Puma Biotechnology, Inc. includes Alan Auerbach (CEO and Board Member), Alan H. Auerbach (CEO and Board Member), Adrian M. Senderowicz (Board Member) and 6 others.
“I will begin with a brief summary of our financial results for the second quarter of 2026. Please note that I will make comparisons to Q1 2026, which we believe is a better indication of our progress as a commercial company than year-over-year comparisons.”
“I will begin with a brief summary of our financial results for the second quarter of 2026. Please note that I will make comparisons to Q1 2026, which we believe is a better indication of our progress as a commercial company than year-over-year comparisons.”
“I will begin with a brief summary of our financial results for the first quarter of 2026. Please note that I will make comparisons to Q4 2025, which we believe is a better indication of our progress as a commercial company than year-over-year comparisons.”
“I will begin with a brief summary of our financial results for the fourth quarter of 2025. Please note that I will make comparisons to Q3 2025, which we believe is a better indication of our progress as a commercial company, and year-over-year comparisons.”
“I will begin with a brief summary of our financial results for the third quarter of 2025. Please note that I will make comparisons to Q2 2025, which we believe is a better indication of our progress as a commercial company than year-over-year comparisons.”
Start not stated–present
Last confirmed April 28, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Puma Biotechnology, Inc. (PBYI) | Chief Financial Officer | $562,961 | $1,241,215 |
| 2024 | Puma Biotechnology, Inc. (PBYI) | Chief Financial Officer | $538,719 | $1,404,978 |
| 2023 | Puma Biotechnology, Inc. (PBYI) | Chief Financial Officer | $515,521 | $1,231,826 |
| 2022 | Puma Biotechnology, Inc. (PBYI) | Chief Financial Officer | $495,693 | $1,071,757 |
| 2021 | Puma Biotechnology, Inc. (PBYI) | Chief Financial Officer | $472,089 | $1,964,260 |
| 2020 | Puma Biotechnology, Inc. (PBYI) | Chief Financial Officer | $460,575 | $979,147 |
| 2019 | Puma Biotechnology, Inc. (PBYI) | Chief Financial Officer | $445,000 | $665,799 |
| 2018 | Puma Biotechnology, Inc. (PBYI) | Chief Financial Officer | $71,029 | $2,281,642 |
